Search Results
Jan 05, 2026, 18:55 ET Everest Medicines to Present at the 44th Annual J.P. Morgan Healthcare Conference
leading global pharmaceutical companies and local Chinese pharmaceutical companies in high-quality discovery, clinical development, regulatory affairs, CMC, business development and operations. Everest Medicines has built a portfolio of potentially global first-in-class or best-in-class molecules in the
More news about: Everest Medicines
Jan 05, 2026, 06:45 ET CMC Announces Quarterly Dividend of $0.18 Per Share
Company ("CMC" or the "Company") (NYSE: CMC) declared a regular quarterly cash dividend of $0.18 per share of CMC common stock. CMC's 245th consecutive quarterly dividend will be paid on February 2, 2026, to stockholders of record as of the close of business on January 19, 2026. About CMCCMC
More news about: Commercial Metals Company
Jan 03, 2026, 09:00 ET TLX 6-DAY DEADLINE ALERT: Hagens Berman Urges Telix Investors to Act by Jan. 9 in Class Action Suit Over SEC Subpoena & FDA CRL on Manufacturing Failures
first the SEC apparently questioning the development disclosures, and then the FDA alleged to have rejected a BLA based on fundamental CMC (Chemistry, Manufacturing, and Controls) and Form 483 deficiencies at the third-party manufacturers," said
More news about: Hagens Berman Sobol Shapiro LLP
Jan 01, 2026, 09:00 ET 21% TLX PLUNGE: Hagens Berman Urges Telix Investors to Act by Jan. 9 in Class Action Suit Over SEC Subpoena & FDA CRL on Manufacturing Failures
first the SEC apparently questioning the development disclosures, and then the FDA alleged to have rejected a BLA based on fundamental CMC (Chemistry, Manufacturing, and Controls) and Form 483 deficiencies at the third-party manufacturers," said
More news about: Hagens Berman Sobol Shapiro LLP
Jan 01, 2026, 09:00 ET ChemPartner Unveils Updated Visual Identity and Digital Experience Reflecting Its Reputation as a Trusted Biopharma Partner
today at chempartner.com, offering intuitive navigation to premier end-to-end capabilities - from discovery chemistry and biologics to DMPK and CMC. The site highlights real-world case studies, data and scientists behind the work, enabling visitors to easily explore and connect ChemPartner's expertise
More news about: ChemPartner
Dec 31, 2025, 12:20 ET TLX DEADLINE: Faruqi & Faruqi Reminds Telix Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 9, 2026
the Biologics License Application for its product TLX250-CDx, which identified "deficiencies relating to the Chemistry, Manufacturing, and Controls (CMC) package." The FDA additionally "documented notices of deficiency (Form 483) issued to two third-party manufacturing and supply chain partners that will
More news about: Faruqi & Faruqi, LLP
Dec 30, 2025, 09:30 ET 21% TLX PLUNGE: Hagens Berman Urges Telix Investors to Act by Jan. 9 in Class Action Suit Over SEC Subpoena & FDA CRL on Manufacturing Failures
first the SEC apparently questioning the development disclosures, and then the FDA alleged to have rejected a BLA based on fundamental CMC (Chemistry, Manufacturing, and Controls) and Form 483 deficiencies at the third-party manufacturers," said
More news about: Hagens Berman Sobol Shapiro LLP
Dec 27, 2025, 15:55 ET 21% TLX PLUNGE: Hagens Berman Urges Telix Investors to Act by Jan. 9 in Class Action Suit Over SEC Subpoena & FDA CRL on Manufacturing Failures
first the SEC apparently questioning the development disclosures, and then the FDA alleged to have rejected a BLA based on fundamental CMC (Chemistry, Manufacturing, and Controls) and Form 483 deficiencies at the third-party manufacturers," said
More news about: Hagens Berman Sobol Shapiro LLP
Dec 24, 2025, 14:50 ET 21% TLX PLUNGE: Hagens Berman Urges Telix Investors to Act by Jan. 9 in Class Action Suit Over SEC Subpoena & FDA CRL on Manufacturing Failures
first the SEC apparently questioning the development disclosures, and then the FDA alleged to have rejected a BLA based on fundamental CMC (Chemistry, Manufacturing, and Controls) and Form 483 deficiencies at the third-party manufacturers," said
More news about: Hagens Berman Sobol Shapiro LLP
Dec 23, 2025, 20:20 ET Nona Biosciences Expands Integrated Discovery-to-Clinical Capabilities Through Strategic Platform Growth
Investigator-Initiated Trials (IITs). This expansion extends Nona's capabilities beyond discovery and IND-enabling activities to further strengthen CMC development, toxicology, and GMP manufacturing capabilities. Through strategic partnerships, platform acquisitions, and internal technology innovations,
More news about: Nona Biosciences
Dec 23, 2025, 10:50 ET SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Telix Pharmaceuticals
the Biologics License Application for its product TLX250-CDx, which identified "deficiencies relating to the Chemistry, Manufacturing, and Controls (CMC) package." The FDA additionally "documented notices of deficiency (Form 483) issued to two third-party manufacturing and supply chain partners that will
More news about: Faruqi & Faruqi, LLP
Dec 23, 2025, 09:54 ET Bybit Claimed Top Spot in 24-Hour Spot Trading Volume, Riding on NIGHT Trading Surge
on the platform. According to data from CoinMarketCap (CMC) on December 22, Bybit dominated the peak of NIGHT's trading frenzy, commanding more than 77% of NIGHT's network-wide trading activity, or $7.6 billion
More news about: Bybit
Dec 23, 2025, 09:49 ET Bybit Claimed Top Spot in 24-Hour Spot Trading Volume, Riding on NIGHT Trading Surge
on the platform. According to data from CoinMarketCap (CMC) on December 22, Bybit dominated the peak of NIGHT's trading frenzy, commanding more than 77% of NIGHT's network-wide trading activity, or $7.6 billion
More news about: Bybit
Dec 23, 2025, 00:03 ET Fapon Biopharma Publishes Pioneering Research in Cell Reports Medicine on FP008, an anti-PD 1 X IL-10M Fusion Protein for Cancer Immunotherapy
established capabilities that cover the entire drug development process from drug discovery, preclinical research, Chemistry, Manufacturing and Controls (CMC) to early clinical development. Committed to innovation, we strive to deliver safer, more efficacious, affordable, and accessible biologics for everyone.For
More news about: Fapon Biopharma
Dec 22, 2025, 08:51 ET 21% TLX PLUNGE: Hagens Berman Urges Telix Investors to Act by Jan. 9 in Class Action Suit Over SEC Subpoena & FDA CRL on Manufacturing Failures
first the SEC apparently questioning the development disclosures, and then the FDA alleged to have rejected a BLA based on fundamental CMC (Chemistry, Manufacturing, and Controls) and Form 483 deficiencies at the third-party manufacturers," said
More news about: Hagens Berman Sobol Shapiro LLP
Dec 21, 2025, 22:52 ET 후지필름비즈니스이노베이션, 필리핀•싱가포르 진출 60주년 및 중국 진출 30주년 맞아
지역이기도 하다.2025년 7월, 후지필름BI는 후지필름 옵틱스 필리핀(FUJIFILM Optics Philippines Inc.)을 아태지역 자원 순환 허브로 육성하기 위해 '서큘러 매뉴팩처링 센터(Circular Manufacturing Centre, CMC)' 설립을 발표했다. 2026년 가동 예정인 이 시설은 후지필름BI 복합기(MFD)의 재제조(Remanufacturing) 공정을 전담하게 된다. 이곳에서 수거된 기기는 부품 단위로 분해, 세척 및 정밀 검사를 거쳐 신제품과 동일한 품질 및 신뢰도 기준으로 재조립되며,
More news about: FUJIFILM Business Innovation
Dec 19, 2025, 09:13 ET TLX LAWSUIT DEADLINE: Hagens Berman Urges Telix Investors to Act by Jan. 9 Over Alleged Dual Regulatory Failures: SEC Subpoena & FDA CRL on CMC/Supply Chain
August 28, 2025, the FDA rejected the Zircaix (TLX250-CDx) application, citing deficiencies in Chemistry, Manufacturing, and Controls (CMC) and documented Form 483 deficiencies at third-party manufacturers.
More news about: Hagens Berman Sobol Shapiro LLP
Dec 19, 2025, 06:45 ET Commercial Metals Applauds Preliminary Ruling Against Algerian Rebar
IRVING, Texas, Dec. 19, 2025 /PRNewswire/ -- Commercial Metals Company (NYSE: CMC) ("CMC" or the "Company") applauds the preliminary ruling issued by the Department of Commerce recognizing that rebar originating from Algeria has been unfairly
More news about: Commercial Metals Company
Dec 18, 2025, 16:15 ET CMC Publishes 2025 Sustainability Report
Peter Matt, President and Chief Executive Officer. "We remain dedicated to making a positive impact on a sustainable future."About CMCCMC is an innovative solutions provider helping build a stronger, safer, and more sustainable world. Through an extensive manufacturing network
More news about: Commercial Metals Company
Dec 17, 2025, 16:15 ET Commercial Metals Announces Credit Facility Amendment
IRVING, Texas, Dec. 17, 2025 /PRNewswire/ -- Commercial Metals Company (NYSE: CMC) ("CMC" or the "Company") today announced that the Company entered into an amendment (the "Amendment") to the credit agreement governing its revolving credit
More news about: Commercial Metals Company
Dec 17, 2025, 16:06 ET TLX LAWSUIT DEADLINE: Hagens Berman Urges Telix Investors to Act by Jan. 9 Over Alleged Dual Regulatory Failures: SEC Subpoena & FDA CRL on CMC/Supply Chain
first the SEC apparently questioning the development disclosures, and then the FDA alleged to have rejected a BLA based on fundamental CMC (Chemistry, Manufacturing, and Controls) and Form 483 deficiencies at the third-party manufacturers," said
More news about: Hagens Berman Sobol Shapiro LLP
Dec 17, 2025, 10:01 ET SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Telix Pharmaceuticals
the Biologics License Application for its product TLX250-CDx, which identified "deficiencies relating to the Chemistry, Manufacturing, and Controls (CMC) package." The FDA additionally "documented notices of deficiency (Form 483) issued to two third-party manufacturing and supply chain partners that will
More news about: Faruqi & Faruqi, LLP
Dec 17, 2025, 08:30 ET Xtalks Releases 2025 Webinar Year-in-Review Showcasing Key Life Science Trends
manufacturing and scalability challenges associated with these complex modalities. The sessions also explored chemistry, manufacturing and control (CMC) strategies across the development lifecycle, from Investigational New Drug (IND)-enabling studies through Biologics License Application (BLA) submission.As
More news about: Xtalks
Dec 16, 2025, 15:39 ET Bioassay Method Transfer Strategies to Reduce Variability, Upcoming Webinar Hosted by Xtalks
objectives and considerations of early-, mid- and late-phase assay transfers and will compare FDA and EMA guidance for assays transferred to and from CMC testing laboratories (ICH Q2(R2), USP <1224> and EU GMP Chapter 6). Case studies will highlight the challenges and present solutions to illustrate
More news about: Xtalks
Dec 15, 2025, 17:31 ET Gene Therapies for Cardiomyopathies Market Poised for Rapid Expansion During the Forecast Period (2025-2034) with Advancements in AAV and CRISPR Platforms | DelveInsight
operational highlights, reported participation in the FDA's Development Readiness Pilot (CDRP) program to accelerate Chemistry, Manufacturing, and Controls (CMC) registration readiness and expects final alignment on the LX2006 registration study in the late third quarter to early fourth quarter 2025.In
More news about: DelveInsight Business Research, LLP